Nanjing Minovay Pharmaceutical has secured hundreds of millions of yuan in a Series B financing round from IDG Capital, which will help "Rongzhi®" further expand its first-mover advantage.
Recently, Minoview Pharmaceuticals successfully completed a hundred-million-yuan Series B financing, exclusively led by the well-known investment institution IDG Capital, with existing shareholder Yuanhe Origin continuing to follow-on invest. It is reported that this round of financing will be mainly used to accelerate the advancement of the innovative drug R & D pipeline, as well as the market promotion and sales layout of its core product, the "Rongzhi®" fat-dissolving injection, injecting strong impetus for the company to maintain its leading position in drug R & D in the consumer healthcare field.
As a rising star in the R & D of innovative drugs for consumer healthcare in China, Minoview Pharmaceuticals recently reached an important milestone: its independently developed DCA deoxycholic acid injection (brand name: Rongzhi®) was successfully approved for marketing in June this year, becoming the first compliant fat-dissolving injection drug in China. This breakthrough not only fills the compliance gap in the domestic fat-dissolving treatment field but also provides a safe and effective treatment option for many beauty seekers with its precise targeting technology advantage.
In terms of product pipeline layout, Minoview Pharmaceuticals' profound technological accumulation is gradually transforming into innovative explosive power. In addition to the already marketed Rongzhi®, the company continues to deeply explore the field of disfiguring diseases. New drugs for indications such as androgenetic alopecia and photoaging will enter the clinical development stage in the fourth quarter of 2025. In the field of mental diseases, the new anti-postpartum depression drug MI078 capsules have completed Phase II clinical research. The unblinded data shows that the drug has reached the preset primary efficacy endpoint, and its efficacy is significantly better than the placebo group. As the first new anti-postpartum depression drug in China to complete Phase II clinical trials, MI078 can safely and effectively cure postpartum depression within three days of oral administration. Its R & D progress is ahead of similar domestic products and is expected to become the first Class 1 innovative drug for the treatment of postpartum depression with independent intellectual property rights in China, becoming an explosive growth engine in the innovative drug track in the fields of mental and disfiguring diseases.
Its core team is led by Liu Fei, a postdoctoral fellow from Tsinghua University and a doctor of medicinal chemistry from China Pharmaceutical University. All team members have over 10 years of industrialization experience in China and the United States, providing a solid guarantee for technology transformation and product implementation.
This financing will make full use of the financial support and resource advantages of IDG Capital to focus on promoting two core strategies and build a dual-wheel drive system of "R & D + commercialization". It is reported that the commercialization of its first domestic fat-dissolving injection, "Rongzhi®", is being carried out simultaneously across the country, aiming at the multi-billion-yuan medical aesthetics consumer market. It is expected to become a benchmark enterprise in the field of innovative drugs for consumer healthcare in the future.
IDG Capital said:
Minoview Pharmaceuticals has achieved remarkable results in a relatively short period of more than four years since its establishment, thanks to its innovative technology platform, rich product pipeline, and excellent management team. The current R & D environment for innovative drugs is full of opportunities and challenges. We are optimistic about Minoview's great potential in the treatment fields of mental diseases and disfiguring diseases. We believe that through this investment, we can help the company further improve its R & D capabilities and accelerate the product commercialization process, enabling it to become a leading innovative drug enterprise in the industry."
Yuanhe Origin said:
Under the leadership of Dr. Liu, the Minoview team has successfully obtained approval for a blockbuster product for marketing in more than four years. In addition, there are product pipelines in Phase II and Phase I clinical trials in the fields of psychiatry and dermatology respectively, forming a gradient product matrix. We have continuously supported Minoview since its establishment more than four years ago. We are optimistic about Minoview becoming a global leading enterprise in the fat-dissolving injection track. We also believe that Minoview will continue to innovate in the fields of "mental beauty" and "image beauty", develop good products that meet clinical needs, and improve the quality of life of ordinary patients.